Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 4/20 | 0.48 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 8/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839298 | 1.00 | UGCG (0.48) | UGCGSCN10AMALT1BRAFSCN9A | |
| SCHEMBL29839326 | 0.89 | UGCG (0.51) | UGCGSCN9AMAPT | |
| SCHEMBL22729643 | 0.89 | UGCG (0.51) | UGCGSCN9AMAPT | |
| SCHEMBL22729530 | 0.86 | UGCG (0.48) | UGCGMALT1SCN9AMAPT | |
| SCHEMBL29839303 | 0.86 | UGCG (0.48) | UGCGMALT1SCN9AMAPT | |
| SCHEMBL22729397 | 0.86 | UGCG (0.67) | UGCGSCN9ANR3C1MAPT | |
| SCHEMBL29839299 | 0.86 | UGCG (0.67) | UGCGSCN9ANR3C1MAPT | |
| SCHEMBL22729450 | 0.85 | UGCG (0.47) | UGCGMALT1SCN9AMAPT | |
| SCHEMBL29839316 | 0.85 | UGCG (0.47) | UGCGMALT1SCN9AMAPT | |
| SCHEMBL22729477 | 0.85 | SCN9A (0.43) | UGCGSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 8/4885SCN10A 2098/4885MALT1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.